financetom
Business
financetom
/
Business
/
ISS recommends TaskUs investors reject proposed deal to take company private
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ISS recommends TaskUs investors reject proposed deal to take company private
Aug 29, 2025 6:34 AM

NEW YORK, Aug 28 (Reuters) - Institutional Shareholder

Services on Thursday urged TaskUs ( TASK ) investors to reject a

plan proposed by investment firm Blackstone and TaskUs' ( TASK )

co-founders to take the outsourcing company that handles content

moderation private.

"There does not appear to be a compelling reason to accept

the terms," the influential proxy advisory firm wrote in its

recommendation that was seen by Reuters. Shareholders are

scheduled to vote on September 10.

ISS argues the offer made by Blackstone and Bryce Maddock

and Jaspar Weir in May to pay $16.50 a share to take the company

private "may have represented a premium at announcement, but it

appears that the unaffected price is not the most appropriate

reference point for value at this stage." The stock closed at

$17.40 on Thursday.

ISS noted that two major shareholders, Murchinson and Think

Investments, have already expressed public opposition to the

deal, arguing the offer is below fair value.

TaskUs ( TASK ) needs the majority of its minority shareholders to

vote in favor of the deal for it to be approved.

The New Braunfels, Texas-headquartered company offers

content moderation, customer experience, artificial intelligence

for companies including DoorDash ( DASH ), Meta and

Uber ( UBER ) and has a market value of roughly $1.6 billion. It

was not immediately available for comment.

ISS recommendations on proposed mergers or other

transactions and proxy fights are widely followed and often help

influence how investors cast their votes.

The ISS report said that any potential revision in deal

terms would "need to narrow the gap in order to adequately

compensate unaffiliated shareholders."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nerdy Insider Bought Shares Worth $432,000, According to a Recent SEC Filing
Nerdy Insider Bought Shares Worth $432,000, According to a Recent SEC Filing
Nov 27, 2024
05:23 PM EST, 11/27/2024 (MT Newswires) -- Charles K. Cohn, 10% Owner, Director, Chief Executive Officer, on Nov. 25, executed a purchase for 300,000 shares in Nerdy ( NRDY ) for $432,000. Following the Form 4 filing with the SEC, Cohn has control over a total of 48,388,009 shares of the company, with 9,258,298 shares held directly and 39,129,711 controlled...
Exco Technologies Reports a Lower Fiscal Fourth-Quarter Profit as Sales Drop
Exco Technologies Reports a Lower Fiscal Fourth-Quarter Profit as Sales Drop
Nov 27, 2024
05:28 PM EST, 11/27/2024 (MT Newswires) -- Exco Technologies ( EXCOF ) after trade Wednesday said its fiscal fourth-quarter profit fell on weaker sales. The auto parts and casting company said it earned $7.7 million, or $0.20 per share, down from $9.2 million, or $0.24, in the same quarter last year. Sales for the quarter ended Sept. 30 fell 3%...
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,309,853, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,309,853, According to a Recent SEC Filing
Nov 27, 2024
05:29 PM EST, 11/27/2024 (MT Newswires) -- Yvonne Greenstreet, Director, Chief Executive Officer, on Nov. 25 and Nov. 26, sold 5,219 shares in Alnylam Pharmaceuticals ( ALNY ) for $1,309,853. Following the Form 4 filing with the SEC, Greenstreet has control over a total of 79,287 shares of the company, with 78,880 shares held directly and 407 controlled indirectly. SEC...
Alnylam Pharmaceuticals Insider Sold Shares Worth $422,144, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $422,144, According to a Recent SEC Filing
Nov 27, 2024
05:29 PM EST, 11/27/2024 (MT Newswires) -- Pushkal Garg, CMO & EVP Dev & Med Affairs, on Nov. 25 and Nov. 26, sold 1,682 shares in Alnylam Pharmaceuticals ( ALNY ) for $422,144. Following the Form 4 filing with the SEC, Garg has control over a total of 18,138 shares of the company, with 17,457 shares held directly and 681...
Copyright 2023-2025 - www.financetom.com All Rights Reserved